Seattle Genetics focuses on developing innovative antibody-based therapies to treat cancer. The biotechnology company is located in Bothell, Washington. It is the leading producer for antibody-drug conjugates (ADCs). The ADCs technology is designed to help minimize the side effects of chemotherapy since it spares non-targeted cells. The company has built a lusty corporate culture based on teamwork, mutual respect, innovation, scientific excellence and integrity. Seattle Genetics is committed to conducting and performing its business with integrity and professionalism.
The company was co-founded in 1998 by Clay B. Siegall. Clay is currently the company’s Chief Executive Officer, President and Chairman of the Board. Clay Siegall worked with the National Cancer Institute and National Institutes of Health before co-founding Seattle Genetics. Siegall received his Bachelor’s degree from the University of Maryland. He also attended George Washington University where he earned his Ph.D. in Genetics.
Clay Siegall is a specialized in targeted cancer therapies. He led the company in securing the 2011 FDA approval and developing ADCs. The companies first ADC was ADCETRIS (brentuximabvedotin). ADCETRIS is now approved in over 60 countries worldwide. Seattle Genetics has joined many strategic licenses with Abbvie, GlaxoSmithKline and Pfizer and Genentech (Roche).In clinical development, Seattle Genetics’ technology is used by over 20 ADCs. Under the leadership of Clay Siegall, the company has secured more than $1.2 billion via private and public financing.
Seattle genetics is currently trying out Adcetris for cancer treatments. The commercialized drug is being tested against different types of Lymphomas. The company’s CEO announced that Seattle Genetics is conducting an advanced trial that uses Adcetris for the treatment of previously untreated Hodgkin lymphoma. The results of the trials are expected to have a big impact on the company. Adcetris has earned the biotechnology company over $220 million in Canadian and U.S. sales in 2015. Seattle Genetics had its first initial public offering (IPO) in 2001.